reports
- Brian Moretta
- Mark Thomas
- Mike Foster
Hardman & Co Monthly: March 2026
Feature article: Tech sector outlook | Small cap finding support at COVID-19 levels The past year has been a challenging period for UK technology stocks. The sector has diverged from buoyant UK blue chips due to the perceived threats of AI-induced disruption. This underperformance has been regardless of generally positive trading news, and larger cap software & services companies have performed significantly worse than their smaller brethren. Takeovers have continued to pick off the remainin...
- Brian Moretta
Chesnara plc (CSN): A positive expansion in Benelux
Chesnara has announced that it is buying Scottish Widows Europe, a closed company with a book consisting of UK products that were sold, pre-Brexit, into Europe, primarily Germany. The consideration is €110m, which will be met from internal resources, notably the proceeds of last year’s Tier 1 bond issue. For this, it adds ca.€1.7bn of AuA and 46,000 policies. It also brings an estimated €250m of future cash generation as the book runs off, with €100m in the first five years. Scottish Widows Euro...
- Brian Moretta
- Mark Thomas
Hardman & Co Monthly: October 2025
Feature article: Building tomorrow’s AI: How the UK will become the global architect of Trustworthy Intelligence In this month’s feature article, Professor Andy Pardoe, Professor of AI and Chair of the Deep Tech Innovation Centre at the University of Warwick, gives his perspective on the artificial intelligence (AI) industry and how it is advancing at an unprecedented pace, outstripping anything witnessed in previous decades. For researchers, industry leaders and investors, understanding the la...
- Brian Moretta
Chesnara plc: Showing good operational progress
Chesnara announced its 1H’25 results. The main features were a better-than-expected operational performance, weaker economic returns and increased central costs but improved cash generation. An Economic Value loss of £11m was behind recent figures (1H’24: profit of £20m). Alongside the dividend payment, this loss reduced the Economic Value, which declined from £531m to £517m in the first half. Cash generation of £37m was a 28% increase over the 1H’24 figure of £29m. The interim dividend, as expe...
- Brian Moretta
Chesnara plc (CSN): Landing the big one
After a longer wait than planned, Chesnara has announced a large acquisition, HSBC Life (UK). At a cost of £260m, it is over 70% of Chesnara’s pre-announcement market capitalisation and will be funded by a mixture of equity, existing cash resources (primarily from the earlier Tier 2 bond issue) and drawing down from a newly increased revolving credit facility. The rights issue should complete by 23 July 2025, with deal completion in early 2026. There is a one-off additional uplift to the dividen...
- Brian Moretta
- Jason Streets
- Mark Thomas
Hardman & Co Monthly: May 2025
Feature article: Attractive asset managers - Radical derating presumes things only get worse The UK asset management sector has been significantly derated over the past couple of years. It has faced the dual problem of a shift towards passives and to private assets and away from traditional listed equities and bonds. However, the sector’s assets haven’t collapsed; its margins have proved relatively robust and its profits fairly stable, even against all the rising costs. The clear implication, ...
- Brian Moretta
Chesnara plc (CSN): Showing good operational progress
Chesnara announced its 2024 results, which showed positive progress compared with 2023. The main features were positive market returns, offset by some mixed operational experience. Economic Value profit of £69.1m represented a 17% increase on the £59.1m in 2023. Economic Value increased to £531m, up slightly on £525m 12 months earlier, with a negative forex impact as well as dividend payment. Cash generation was excellent, with base cash increasing to £51.6m and commercial cash to £59.6m. The di...
Hardman & Co research on Chesnara plc (CSN): Showing good operational ...
Hardman & Co Research Hardman & Co research on Chesnara plc (CSN): Showing good operational progress 07-Apr-2025 / 14:20 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Chesnara plc (CSN): Showing good operational progress Chesnara announced its 2024 results, which showed positive progress compared with 2023. The main features were positive market returns, offset by some mixed operational experience. Economic Value profit of £69.1m represented a 17% increase on the £59.1m in 2023. Economic Value increased to £531m, up ...
Chesnara: 2 directors
Two Directors at Chesnara bought 25,695 shares at between 271p and 272p. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
- Brian Moretta
- Mark Thomas
- Martin Hall
Hardman & Co Monthly: January 2025
Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...
CLBX CELLBXHEALTH PLC
DEMG DELTEX MEDICAL GROUP PLC
TSTL TRISTEL PLC
TRX TISSUE REGENIX GROUP
EKF EKF DIAGNOSTICS HOLDINGS
ODX OMEGA DIAGNOSTICS
AVCT AVACTA GROUP
PHP PRIMARY HEALTH PROPERTIES PLC
AGY ALLERGY THERAPEUTICS PLC
ARBB ARBUTHNOT BANKING GROUP
APH ALLIANCE PHARMA PLC
FUM FUTURA MEDICAL PLC
ALNOV NOVACYT SAS
VLG VENTURE LIFE GROUP
RECI REAL ESTATE CREDIT INVESTMENTS
IMM IMMUPHARMA
PRM PROTEOME SCIENCES PLC
ACSO ACCESSO TECHNOLOGY GROUP
GNS GENUS PLC
SUN SURGICAL INNOVATIONS GROUP PLC
AMS ADVANCED MEDICAL SOLUTIONS GROUP PLC
OMG OXFORD METRICS
EAH ECO ANIMAL HEALTH GROUP
JDG JUDGES SCIENTIFIC
VTAS VOLTA FINANCE (GBP)
SDI SDI GROUP
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
FARON FARON PHARMACEUTICALS OY
ONC ONCIMMUNE HOLDINGS
STX SHIELD THERAPEUTICS
CSN CHESNARA PLC
SNG SYNAIRGEN PLC
IPO IP GROUP
HAT H&T GROUP
SCLP SCANCELL HOLDINGS
SYNC SYNCONA
CIR CIRCASSIA GROUP
SPI SPIRE HEALTHCARE GROUP PLC
AGR ASSURA PLC
APAX APAX GLOBAL ALPHA
ICGT ICG ENTERPRISE TRUST
GDR GENEDRIVE
CTEC CONVATEC GROUP PLC
CREO CREO MEDICAL GROUP
SBTX SKINBIOTHERAPEUTICS
A0MXLB NB PRIVATE EQUITY PARTNERS
FAB FUSION ANTIBODIES
IXI IXICO
OXB OXFORD BIOMEDICA PLC
ABDX ABINGDON HEALTH
IMCR IMMUNOCORE HOLDINGS ADS
POLX POLAREAN IMAGING
AREC ARECOR THERAPEUTICS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
SAR SAREUM HOLDINGS PLC
BAI BENEVOLENTAI
4BB 4BASEBIO PLC
TISSUE REGENIX GROUP PLC
- Brian Moretta
Chesnara plc: Happy new acquisition
After an interval of 18 months, Chesnara announced a new acquisition just before Christmas. Although relatively small, it is another positive step for the company. The deal is a further acquisition from Canada Life UK, this time a portfolio of unit-linked bonds and legacy pension business, consisting of ca.17,000 policies and £1.5bn of AUM. The portfolio will transfer into Chesnara’s UK business, Countrywide Assured. Expected completion is at the end of 2025, subject to the Part VII transfer get...
Hardman & Research on Chesnara plc: Happy new acquisition
Hardman & Co Research Hardman & Research on Chesnara plc: Happy new acquisition 09-Jan-2025 / 09:20 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Chesnara plc: Happy new acquisition After an interval of 18 months, Chesnara announced a new acquisition just before Christmas. Although relatively small, it is another positive step for the company. The deal is a further acquisition from Canada Life UK, this time a portfolio of unit-linked bonds and legacy pension business, consisting of ca.17,000 policies and £1.5bn of AUM. T...
Hardman & Co Q&A on Chesnara plc (CSN): 2024 interim results a steady ...
Hardman & Co Research Hardman & Co Q&A on Chesnara plc (CSN): 2024 interim results a steady performance 11-Oct-2024 / 09:50 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co analyst interview | Life assurance Q&A on Chesnara plc (CSN) | 2024 interim results a steady performance Chesnara plc is the topic of conversation when Hardman & Co analyst, Brian Moretta joins DirectorsTalk. In this interview with Brian, key insights are provided on Chesnara plc following the release of its 2024 interim results. The interview touches on Chesnara’s...
- Brian Moretta
- Keith Hiscock
- Mark Thomas
- Martin Hall
Hardman & Co Monthly: October 2024
Feature article: Labour’s first Budget - Investors in their sights? Summary ► Budgets are always important for investors. ► The imminent Budget, at the end of October, will be doubly so, because it is the first from the new Labour government, and it has already signalled the need to fill an alleged £22bn black hole, while ruling out changes to more than half the tax base. That implies a lot of the pain will be felt by investors. ► This paper considers the impact of increases in rates for th...
Hardman Talks Video | Chesnara plc (CSN): Presentation and Q&A with Ma...
Hardman & Co Research Hardman Talks Video | Chesnara plc (CSN): Presentation and Q&A with Management 01-Oct-2024 / 11:30 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman Talks Video | Chesnara (CSN) Presentation and Q&A with Management In this episode of Hardman Talks, our Financials analyst Brian Moretta introduces Chesnara‘s CEO Steve Murray and CFO Tom Howard to discuss Chesnara’s recent interim results. Watch it here: Steve presents an overview of Chesnara's strong performance, highlighting cash generation, a robust balance sheet, an...
Hardman & Co Research on Apax Global Alpha (APAX): 1H’24 deal activit...
Hardman & Co Research Hardman & Co Research on Apax Global Alpha (APAX): 1H’24 deal activity coming back strongly 26-Sep-2024 / 11:36 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Apax Global Alpha (APAX): 1H’24 deal activity coming back strongly The key messages from AGA’s were i) a strong rebound in deal activity both for investments and exits (the regular announcements mean this trend was expected), ii) strong growth in investee company EBITDA growth (organic 12.6%, up from 12.2% in FY’23) ‒ widening margins ref...
- Brian Moretta
Chesnara Plc (CSN): Steady as she goes!
Chesnara has announced its 1H’24 results. The main features were positive equity market returns, offset to some extent by further adverse lapse experience. Economic Value profit of £20.2m was behind the 1H’23 result of £32.6m (excl. acquisitions). Economic Value saw a small decline to £508m, from £525m at the year-end, with the dividend payment and forex losses offsetting the earnings. Cash generation was solid, with base cash of £19.6m and commercial cash generation of £29.2m. The interim divid...
Hardman & Co Research on Chesnara Plc (CSN): Steady as she goes!
Hardman & Co Research Hardman & Co Research on Chesnara Plc (CSN): Steady as she goes! 26-Sep-2024 / 08:15 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Chesnara Plc (CSN): Steady as she goes! Chesnara has announced its 1H’24 results. The main features were positive equity market returns, offset to some extent by further adverse lapse experience. Economic Value profit of £20.2m was behind the 1H’23 result of £32.6m (excl. acquisitions). Economic Value saw a small decline to £508m, from £525m at the year-end, with the d...
Hardman Talks Video | Chesnara plc (CSN) Management Presentation and Q...
Hardman & Co Research Hardman Talks Video | Chesnara plc (CSN) Management Presentation and Q&A 06-Jun-2024 / 15:30 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman Talks Video | Chesnara plc (CSN) Management Presentation and Q&A In the latest Hardman Talks, Chesnara CEO Steve Murray and CFO Tom Howard join Hardman & Co analyst Brian Moretta to discuss their 2023 results and prospects. Management give a brief presentation, discussing recent progress, including M&A developments, recent cash generation and future prospects as well as financ...
Q&A on Chesnara plc (CSN): Growth and stability insights
Hardman & Co Research Q&A on Chesnara plc (CSN): Growth and stability insights 09-May-2024 / 14:04 GMT/BST The issuer is solely responsible for the content of this announcement. Analyst interview | Financials Q&A on Chesnara plc (CSN) | Growth and stability insights Chesnara (LON:CSN) is the topic of conversation when Hardman & Co analyst Brian Moretta joins DirectorsTalk Interviews. Brian delves into Chesnara plc’s 2023 financial results. He shares his analysis on the factors driving Chesnara’s recovery from a previous year’s loss, the impact of global economic shifts on ope...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.